GLP-1 (Glucagon-Like Peptide-1)
Definition
GLP-1 is an incretin hormone released by cells in the small intestine in response to eating. It triggers insulin secretion, suppresses glucagon, slows gastric emptying, and signals the brain to reduce hunger. GLP-1 receptor agonists — synthetic versions including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — mimic this hormone at therapeutic doses. Clinical trials have demonstrated average weight reductions of 15 to 22% of body weight alongside improvements in blood sugar, cardiovascular markers, and metabolic function. These medications do not simply suppress appetite mechanically — they restore a hormonal signaling process that is often blunted in people with insulin resistance or obesity.
Frequently Asked Question
Why GLP-1 (Glucagon-Like Peptide-1) Matters
How Spokmed Company Uses It
Michelle Middleton, PA-C has been prescribing GLP-1 medications since mid-2021 — before they became widely known. At SPOKEmed, GLP-1 therapy is never prescribed in isolation. It is part of a comprehensive protocol that includes metabolic testing, nutritional guidance (including protein optimization and structured meal timing), health coaching, and follow-up every 3 to 4 weeks to monitor response and adjust dosing.